Overview

Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia

Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
0
Participant gender:
All
Summary
This study plans to learn more about the effects of levetiracetam (LEV) on brain activity and cognition in schizophrenia and schizoaffective disorder. Levetiracetam is an anti-seizure drug, also called an anticonvulsant.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
VA Office of Research and Development
Treatments:
Etiracetam
Levetiracetam
Piracetam
Criteria
Inclusion Criteria:

- Diagnosis of schizophrenia or schizoaffective disorder

- Good general health

- Normal vital signs (blood pressure, pulse, respiration)

Exclusion Criteria:

- Substance abuse

- Significant neurological disorders

- Significant head trauma/injury

- Pregnancy

- MRI-specific exclusion criteria, e.g.,:

- claustrophobia

- weight>400 lbs

- metal in the body